Equillium is a La Jolla biotechnology company developing treatments for autoimmune and inflammatory diseases, starting with ulcerative colitis. It last closed at $1.21 on Nov 17, up 5.22% on the day.
Only 1 firm rated EQ in the past 90 days, not enough for a consensus
Average 12-month target
$12.00
▲ 891.7% upside
Based on 1 analyst who set a price target on EQ in the past 90 days. The average target is $12.00, with a high of $12.00 and a low of $12.00, compared with the last close of $1.21.
Low $12.00Avg $12.00High $12.00
Blue marker: last close $1.21
Highest target$12.00
Average target$12.00
Lowest target$12.00
Latest rating changes
Roth CapitalReiterated
Sep 4Buy$12
Piper SandlerInitiated
Jul 13Buy$20
Leerink PartnersUpgrade
May 28Buy$6
B. Riley SecuritiesInitiated
Apr 16Buy$6
Raymond JamesInitiated
Apr 14Buy$6
Date
Firm
Action
Rating
Price target
Sep 4
Roth Capital
Reiterated
Buy
$12
Jul 13
Piper Sandler
Initiated
Buy
$20
May 28
Leerink Partners
Upgrade
Buy
$6
Apr 16
B. Riley Securities
Initiated
Buy
$6
Apr 14
Raymond James
Initiated
Buy
$6
Loading…
Technical Analysis
EQ · as of the Nov 17 close · updated after every close
Downtrend
The stock is 12% below its 20 day and 28% below its 50 day average. It is 72% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the Pivot at $1.20, and the nearest resistance the Pivot R1 at $1.25.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 10.1%/day
Key levels
$3.5452 week high+192.6%
$2.09200 day average+72.7%
$2.01100 day average+66.1%
$1.5550 day average+28.1%
$1.48Swing high (Oct 29)+22.3%
$1.3620 day average+12.4%
$1.25Pivot R1+3.3%
$1.21Last close
$1.20Pivot−0.8%
$1.17Swing low (Oct 26)−3.3%
$1.16Pivot S1−4.1%
$0.8152 week low−33.1%
Indicators
RSI (14)
38.70
Weak, oversold below 30
Neutral
MACD
-0.07
Below its signal line
Bearish
Stochastic
10.9
Near the bottom of its range
Oversold
ADX (14)
18.3
No clear trend
Williams %R
-85.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-136.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−14.2%
Change over 10 sessions
Bearish
ATR (14)
$0.12
Typical daily range, 10.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 30.5%/day
Key levels
$3.5452 week high+192.6%
$2.09200 day average+72.7%
$2.01100 day average+66.1%
$1.5550 day average+28.1%
$1.48Swing high (Oct 29)+22.3%
$1.3620 day average+12.4%
$1.25Pivot R1+3.3%
$1.21Last close
$1.20Pivot−0.8%
$1.17Swing low (Oct 26)−3.3%
$1.16Pivot S1−4.1%
$0.8152 week low−33.1%
Indicators
RSI (14)
34.96
Weak, oversold below 30
Neutral
MACD
-0.25
Below its signal line
Bearish
Stochastic
12.4
Near the bottom of its range
Oversold
ADX (14)
20.9
Weak trend
Williams %R
-95.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-100.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−42.6%
Change over 10 sessions
Bearish
ATR (14)
$0.37
Typical daily range, 30.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for EQ
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how EQ did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow EQ usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How EQ has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EQ is in one of them and how their past EQ trades turned out.
Equillium is a biotechnology company in La Jolla, California, that develops treatments for severe autoimmune and inflammatory diseases. Its lead candidate, EQ504, works on the aryl hydrocarbon receptor and is being developed first for ulcerative colitis and other gut diseases. The company also has an oral candidate, EQ302, that blocks two inflammatory signaling proteins and is aimed at celiac disease. Both candidates are still in development and not yet sold, with patients who have gut and immune disorders as the intended users.